AzTrials
AzTrials

Advanced Pancreatic Ductal AdenocarcinomaPhase 2NCT05632328

AGEN1423 and Botensilimab w/ or w/o Chemo in PDAC

A Phase 2 study testing AGEN1423, Botensilimab and Gemcitabine in people with Advanced Pancreatic Ductal Adenocarcinoma and Pancreatic Ductal Adenocarcinoma, run by Bruno Bockorny at 1 site in United States.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

The goal of this research study is to asses the safety and efficacy of the combination of AGEN1423 and Botensilimab with or without chemotherapies, gemcitabine and nab-paclitaxel, for the treatment of advanced pancreatic ductal adenocarcinoma (PDAC) which has progressed after at least one previous line of cancer… Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
AGEN1423, Botensilimab and Gemcitabine
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
24 participants
Where
1 siteUnited States
Study dates
8 Aug 2024to 1 Apr 2027
Phase
Phase 2
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • 18 year and older
  • Ability to understand and willingness to sign a written informed consent prior to entering the study.
  • Histologically or cytologically confirmed (either previously or newly biopsied) metastatic or locally advanced unresectable pancreatic adenocarcinoma, including intraductal papillary mucinous neoplasm.
  • Have measurable disease (≥ 1 measurable lesion) based on RECIST v1.1 as determined by the site study team. Tumor lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.
  • Previous treatment lines
  • Cohort 1: Have documented objective radiographic progression on or after stopping treatment with first-line or further therapy, i.e. chemotherapy and or radiotherapy. If subjects received prior neoadjuvant or adjuvant chemotherapy and progressed within 3 months of the last dose, then this should be considered as a prior line of systemic therapy.
Show all 34Show fewer
  • Cohort 2: Have documented objective radiographic progression on or after stopping treatment with first-line, fluorouracil-based chemotherapy.
  • For Cohort 1, willing to submit an evaluable fresh tumor tissue sample, unless tumor is considered inaccessible, or biopsy is otherwise considered not in the subject's best interest.
  • Complete resolution of toxic effect(s) of the most recent prior chemotherapy to Grade 1 or less (except alopecia and peripheral neuropathy). If the subject received major surgery or radiation therapy of > 30 Gy, they must have recovered from the toxicity and/or complications from the intervention.
  • ECOG status ≤1
  • Life expectancy of at least 3 months
  • Participants must have adequate organ and marrow function as defined below. All laboratory assessments should be performed within 10 days of treatment initiation
  • Hematological:
  • Hemoglobin ≥ 9g/dL (without transfusion within 7 days of assessment)
  • Leukocytes ≥3,000/µL
  • Absolute neutrophil count ≥1,500/µL
  • Absolute lymphocyte count ≥700/µL
  • Platelets ≥100,000/µL
  • Hepatic Function
  • Total bilirubin ≤ 1.5 institutional upper limit of normal (ULN)
  • AST(SGOT)/ALT(SGPT) ≤3 × institutional ULN
  • Renal Function
  • ---Creatinine Clearance > 50 mL/min as calculated per Cockcroft-Gault formula
  • Nutritional
  • ---Serum Albumin ≥ 3 g/dL
  • Coagulation
  • INR or PT: ≤1.5xULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants.
  • aPTT: ≤1.5xULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants
  • Subjects must use effective contraception:
  • Female subjects must be of non-childbearing potential or, if of childbearing potential, must agree to use a highly effective method of birth control (Appendix B), during the study and for 6 months following the last dose of study medication and must have a negative urine or serum pregnancy test within 72 hours prior to taking study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. The serum pregnancy test must be negative for the subject to be eligible. Non-childbearing potential is defined as (by other than medical reasons):
  • ---≥45 years of age and has not had menses for over 2 years
  • ---Amenorrhoeic for > 2 years without a hysterectomy and oophorectomy
  • Post hysterectomy, bilateral oophorectomy, bilateral salpingectomy or bilateral tubal ligation at least 6 weeks prior to Screening. Information must be captured appropriately within the medical records.
  • Male subjects must agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy.

Who cannot join

  • Has a pancreatic tumor other than adenocarcinoma, including: adenosquamous, acinar cell carcinoma, pancreaticoblastoma, malignant cystic neoplasms, endocrine neoplasms, squamous cell carcinoma, Vater and periampullary duodenal or common bile duct malignancies.
  • Subjects with a bowel obstruction.
  • Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent.
  • Has an active infection requiring systemic therapy or has an uncontrolled infection.
  • Has an underlying medical condition that would preclude study participation.
  • Has a disease that is suitable for therapy administered with curative intent.
Show all 25Show fewer
  • Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
  • Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment
  • Has had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at Baseline) from AE due to agents administered more than 4 weeks earlier.
  • Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or has not recovered (i.e., ≤ Grade 1 or at Baseline) from AE due to a previously administered agent (Subjects with ≤ Grade 2 neuropathy or ≤ Grade 2 alopecia are an exception to this criterion and may qualify for the study. If subject underwent major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy)
  • An active autoimmune disease that has required systemic treatment in the 2 years preceding the study (i.e., with the use of disease-modifying agents, corticosteroids or immuno-suppressive drugs). Note: Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment and is allowed.
  • Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis.
  • Has a history of interstitial lung disease.
  • O2 saturation < 92% (on room air).
  • Has unstable angina, new onset angina within the last 3 months, myocardial infarction within the last 6 months, and current congestive heart failure New York Heart Association Class III or higher. For Cohort 2: has ventricular arrhythmias, hypertensive urgency, or severe arterial thromboembolic events less than 6 months prior to study initiation.
  • Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating Investigator.
  • Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
  • Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the trial, starting with the Screening visit through 120 days after the last dose of trial treatment. Women with a positive pregnancy test within 72 hours from Baseline.
  • Has a positive Human immunodeficiency virus (HIV) positive test. Participants with HIV positive test on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.
  • Has known history of Chronic Hepatitis B or C. For participants with evidence of chronic hepatitis B virus (HBV) infection, if the HBV viral load is undetectable while on suppressive therapy the subject can participate on the study. Participants with a history of hepatitis C virus (HCV) infection must have been treated and cured. For participants with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.
  • Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Note: Subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging using the identical imaging modality for each assessment, either MRI or computerized tomography (CT) scan, for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 14 days prior to trial treatment. This exception does not include carcinomatous meningitis which is excluded regardless of clinical stability.
  • Has received a live vaccine within 30 days of the planned start of study therapy. Seasonal flu vaccines or COVID-19 vaccines that do not contain live virus are permitted.
  • Drainage of ascitic or pleural fluid 2 or more times in the 4 weeks prior to the first dose of study drug or permanent drain in place (eg, PleurX®) for ascites or pleural effusion symptom management.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition of AGEN1423 or Botensilimab.
  • Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer.

Trial locations and contacts

1 site in 1 country.

United States1 site

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts, 02215

Other trials in United States

About this study

Official title: A Phase 2 Study of AGEN1423, an Anti-CD73-TGFβ-Trap Bifunctional Antibody, in Combination With Botensilimab, With or Without Chemotherapy in Subjects With Advanced Pancreatic Cancer.

The goal of this research study is to asses the safety and efficacy of the combination of AGEN1423 and Botensilimab with or without chemotherapies, gemcitabine and nab-paclitaxel, for the treatment of advanced pancreatic ductal adenocarcinoma (PDAC) which has progressed after at least one previous line of cancer therapy.

The names of the study drugs involved in this study are:

  • AGEN1423
  • Botensilimab

Participants will receive study treatment for about 2 years and will be followed for 1 year after.

Read the detailed description

The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits.

  • Participants will receive study treatment for about 2 years and will be followed for 1 year. If the combination is considered to be safe and tolerable, and objective response is achieved in at least 2 patients, the study will proceed to Cohort 2.
  • This research study involves immunotherapy. The names of the study drugs involved in this study are:
  • AGEN1423
  • Botensilimab

It is expected that about 24 people will take part in this part of this research

This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific disease. "Investigational" means that the drug is being studied. The U.S. Food and Drug Administration (FDA) has not approved AGEN1423 as a treatment for any disease. The U.S. Food and Drug Administration (FDA) has not approved Botensilimab as a treatment for any disease.

Agenus, a pharmaceutical company, is supporting this research study by providing funding and study drug for the research study.

Being tested
AGEN1423, Botensilimab, Gemcitabine, Nab-paclitaxel
Keywords
Advanced Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, Chemotherapy, Immunotherapy, AGEN1423, Botensilimab
Medical subject headings
Pancreatic Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • AGEN1423Drug

    Also called Anti-CD73-TGFβ-Trap Bifunctional Antibody

    via IV, dosage per protocol, once every 2 weeks for up to 8 weeks

  • BotensilimabDrug

    via IV, dosage per protocol, once evert 2 weeks, up to 2 years

  • GemcitabineDrug

    Also called Gemzar

    per standard care

  • Nab-paclitaxelDrug

    Also called Abraxane

    per standard care

Study groups in NCT05632328
Study groupRoleWhat they receive
COHORT 1: AGEN1423 Plus BotensilimabExperimentalTreatment is AGEN1423 plus Botensilimab for 4 cycles (8 weeks) followed by Botensilimab alone for up to 2 years. AGEN1423 will be administered in a total of 4 doses. Botensilimab will be administered every 2 weeks.
Receives: Drug: AGEN1423; Drug: Botensilimab
COHORT 2: AGEN1423 Plus Botensilimab and ChemotherapyExperimentalTreatment is AGEN1423 plus Botensilimab in combination with gemcitabine and nab-paclitaxel for 2 cycles (8 weeks) followed by Botensilimab in combination with gemcitabine and nab-paclitaxel for up to 2 years. AGEN1423 will be administered in a total of 4 doses. Botensilimab will be administered once every 2 weeks.
Receives: Drug: AGEN1423; Drug: Botensilimab; Drug: Gemcitabine; Drug: Nab-paclitaxel

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Objective Response Rate

    The objective response rate (ORR) is defined as the proportion of participants achieving complete response (CR) or partial response (PR) based on RECISTv1.1 criteria, using the modified intent-to-treat (mITT) analysis set

    Measured: Every 8 weeks until EOT, for up to 2 years.

Secondary outcomes (5)

  1. Disease Control Rate

    Disease control rate (DCR) defined as the sum of stable disease, partial and complete responses according to RECISTv1.1 criteria.

    Measured: Every 8 weeks from first day of treatment until EOT for both cohorts up to 2 years.

  2. Median Duration of Overall Response (DOR)

    Duration of Overall Response (DOR), estimated using the Kaplan Meier method, is measured from the time measurement criteria are met for CR or PR (whichever is first recorded) per RECISTv1.1, until the first date that recurrent or progressive disease is objectively documented. Patients without progressive disease are censored at the date of last disease assessment.

    Measured: Up to approximately 2 years

  3. Median Overall Survival (OS)

    Overall Survival (OS) based on the Kaplan-Meier method is defined as the time from study entry to death or censored at date last known alive.

    Measured: Up to 2 Years

  4. Median Progression-free Survival

    Progression-free survival based on the Kaplan-Meier method is defined as the duration between randomization and documented disease progression (PD) or death, or is censored at time of last dsease assessment.

    Measured: Every 8 weeks from first day of treatment until EOT for both cohorts up to 4 Years

  5. Grade 3-5 Treatment-related Toxicity Rate

    All grade 3-5 adverse events (AE) with treatment attribution of possibly, probably or definite based on CTCAEv5 that are not resolved in accordance with treatment guidelines were counted. Rate is the proportion of treated participants experiencing at least one of these adverse events as defined during the time of observation.

    Measured: For Cohort 1 AE evaluated on Cycle 1 days 1 and 8, and Day 1 of each subsequent cycle (each cycle is 14 days). For Cohort 2 AE evaluated on Cycle 1 days 1, 8 and 15 of each cycle (each cycle is 28 days).

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted30 Nov 2022
  2. Study start8 Aug 2024
  3. Primary completion4 Aug 2026 (estimated)
  4. Study completion1 Apr 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
24 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05632328
Sponsor's protocol ID
22-213
Status last verified
Jul 2026
First submitted
9 Nov 2022
Last updated
9 Jul 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes: The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: \[contact information for Sponsor Investigator or designee\]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing AGEN1423, Botensilimab and Gemcitabine in people with Advanced Pancreatic Ductal Adenocarcinoma and Pancreatic Ductal Adenocarcinoma, run by Bruno Bockorny at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 34 inclusion and 25 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 9 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Objective Response Rate (time frame: Every 8 weeks until EOT, for up to 2 years.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05632328.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Jul 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in